SV2013004582A - Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias - Google Patents
Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherenciasInfo
- Publication number
- SV2013004582A SV2013004582A SV2013004582A SV2013004582A SV2013004582A SV 2013004582 A SV2013004582 A SV 2013004582A SV 2013004582 A SV2013004582 A SV 2013004582A SV 2013004582 A SV2013004582 A SV 2013004582A SV 2013004582 A SV2013004582 A SV 2013004582A
- Authority
- SV
- El Salvador
- Prior art keywords
- treatment
- prevention
- compounds
- adherences
- pharmaceutical compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 2
- 239000000126 substance Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
- C08G73/0605—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
- C08L79/04—Polycondensates having nitrogen-containing heterocyclic rings in the main chain; Polyhydrazides; Polyamide acids or similar polyimide precursors
- C08L79/06—Polyhydrazides; Polytriazoles; Polyamino-triazoles; Polyoxadiazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA INVENCIÓN SE REFIERE AL CAMPO DE LA FARMACIA, MEDICINA CLÍNICA Y EXPERIMENTAL Y LA MEDICINA VETERINARIA, Y EN PARTICULAR, A NUEVOS COMPUESTOS INHIBITORIOS DE UNA P38 MAP QUINASA CON UNA ESTRUCTURA DEL TIPO (I) - (VII) QUE PUEDEN SER UTILIZADOS PARA EL TRATAMIENTO O LA PROFILAXIS DE ADHERENCIA. LA INVENCIÓN DA A CONOCER COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN UNA CANTIDAD EFICAZ DE LA SUSTANCIA SB203580 O UNO DE LOS COMPUESTOS DEL TIPO (I) (VII) O UNA COMBINACIÓN DE LOS MISMOS Y UN VEHÍCULO FARMACÉUTICAMENTE ACEPTABLE, UN DILUYENTE O UN EXCIPIENTE. TAMBIÉN SE DESCRIBE EL USO DE LA SUSTANCIA SB203580 COMO UN AGENTE QUE TIENE ACTIVIDAD ANTI-ADHERENCIA. TAMBIÉN SE DESCRIBE: UN MÉTODO PARA LA PROFILAXIS Y/O TRATAMIENTO DE UNA ENFERMEDAD O UNA CONDICIÓN EN LA CUAL EXISTE LA POSIBILIDAD DE LA FORMACIÓN Y/O EL CRECIMIENTO DE LAS ADHERENCIAS QUE HACE QUE SEA POSIBLE PRESCINDIR DE LA ADMINISTRACIÓN ADICIONAL DE UNA PREPARACIÓN EN EL PERÍODO POSTOPERATORIO
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2011119848/15A RU2011119848A (ru) | 2011-05-17 | 2011-05-17 | Способ профилактики спайкообразования |
| RU2011153043 | 2011-12-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2013004582A true SV2013004582A (es) | 2018-11-12 |
Family
ID=47176372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2013004582A SV2013004582A (es) | 2011-05-17 | 2013-11-15 | Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US10172952B2 (es) |
| EP (2) | EP2716684B1 (es) |
| JP (2) | JP5936683B2 (es) |
| KR (2) | KR20170034950A (es) |
| CN (1) | CN103534293B (es) |
| AP (1) | AP3694A (es) |
| AU (3) | AU2012257347A1 (es) |
| BR (1) | BR112013029616B1 (es) |
| CA (1) | CA2836268C (es) |
| CL (1) | CL2013003305A1 (es) |
| CO (1) | CO6801779A2 (es) |
| CR (1) | CR20130600A (es) |
| CY (1) | CY1122190T1 (es) |
| DK (1) | DK2716684T3 (es) |
| DO (1) | DOP2013000266A (es) |
| EA (1) | EA025493B1 (es) |
| GE (1) | GEP201706614B (es) |
| IL (1) | IL229423B (es) |
| LT (1) | LT2716684T (es) |
| MA (1) | MA35189B1 (es) |
| MX (2) | MX369019B (es) |
| NI (1) | NI201300124A (es) |
| PE (1) | PE20141161A1 (es) |
| PH (1) | PH12013502381B1 (es) |
| PL (1) | PL2716684T3 (es) |
| RS (1) | RS59382B1 (es) |
| RU (1) | RU2582975C2 (es) |
| SI (1) | SI2716684T1 (es) |
| SV (1) | SV2013004582A (es) |
| WO (1) | WO2012156938A1 (es) |
| ZA (1) | ZA201308542B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA025493B1 (ru) * | 2011-05-17 | 2016-12-30 | Акционерное Общество "Фармасинтез" | Соединения, фармацевтические композиции и способ профилактики и лечения спаечного процесса |
| RU2745965C1 (ru) * | 2020-11-23 | 2021-04-05 | Галина Анатольевна Пучкина | Способ профилактики послеоперационного спаечного процесса органов малого таза |
| RU2749435C1 (ru) * | 2020-11-27 | 2021-06-10 | Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" | Способ лечения энтеральной недостаточности при воспалительных и травматических повреждениях брюшины |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA945363B (en) * | 1993-07-21 | 1995-03-14 | Smithkline Beecham Corp | Novel compounds |
| US20020028798A1 (en) * | 1995-12-12 | 2002-03-07 | Omeros Medical Systems | Irrigation solution and method for inhibition of pain and inflammation |
| US5837719A (en) * | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
| WO1997005878A1 (en) * | 1995-08-10 | 1997-02-20 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
| US5894971A (en) | 1998-02-02 | 1999-04-20 | Huang; Te Chien | Tool holder for attaching tools to user's hand |
| US6521223B1 (en) | 2000-02-14 | 2003-02-18 | Genzyme Corporation | Single phase gels for the prevention of adhesions |
| CA2419633C (en) * | 2000-08-17 | 2011-05-10 | Pfizer Inc. | Substituted imidazoles as tafia inhibitors |
| AU2003249977A1 (en) * | 2002-07-05 | 2004-01-23 | Axxima Pharmaceuticals Ag | Imidazole compounds for the treatment of hepatitis c virus infections |
| WO2004060405A2 (en) * | 2002-12-30 | 2004-07-22 | Angiotech International Ag | Tissue reactive compounds and compositions and uses thereof |
| US7728013B2 (en) * | 2005-05-10 | 2010-06-01 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
| CN101443044A (zh) * | 2005-09-22 | 2009-05-27 | 哈达斯特医学研究服务与开发有限公司 | 治疗活性化合物的葡聚糖和阿拉伯半乳聚糖结合物 |
| CN101535308A (zh) * | 2006-11-09 | 2009-09-16 | 霍夫曼-拉罗奇有限公司 | 作为激酶抑制剂的取代的6-苯基-吡啶并[2，3-d]嘧啶-7-酮衍生物及其使用方法 |
| JP5530635B2 (ja) * | 2007-02-14 | 2014-06-25 | 独立行政法人科学技術振興機構 | 腸管癒着抑制剤 |
| WO2009028965A1 (en) * | 2007-08-28 | 2009-03-05 | Theodore Athanasiadis | Surgical hydrogel |
| RU2363476C1 (ru) | 2007-12-20 | 2009-08-10 | Марина Сергеевна Гомон | Способ профилактики образования послеоперационных спаек |
| WO2009103821A2 (de) * | 2008-02-23 | 2009-08-27 | Virologik Gmbh | Mittel zur behandlung von virusinfektionen |
| US8205286B1 (en) | 2008-10-21 | 2012-06-26 | Milagros Diaz | Pillow for female breasts |
| EA025493B1 (ru) * | 2011-05-17 | 2016-12-30 | Акционерное Общество "Фармасинтез" | Соединения, фармацевтические композиции и способ профилактики и лечения спаечного процесса |
| US20140259423A1 (en) | 2013-03-13 | 2014-09-18 | Evan Joseph FALCK | Helmet Pillow |
-
2012
- 2012-05-17 EA EA201301275A patent/EA025493B1/ru unknown
- 2012-05-17 PH PH1/2013/502381A patent/PH12013502381B1/en unknown
- 2012-05-17 WO PCT/IB2012/052483 patent/WO2012156938A1/ru not_active Ceased
- 2012-05-17 LT LTEP12785811.6T patent/LT2716684T/lt unknown
- 2012-05-17 JP JP2014510934A patent/JP5936683B2/ja not_active Expired - Fee Related
- 2012-05-17 CN CN201280023192.7A patent/CN103534293B/zh not_active Expired - Fee Related
- 2012-05-17 MX MX2013013409A patent/MX369019B/es active IP Right Grant
- 2012-05-17 EP EP12785811.6A patent/EP2716684B1/en active Active
- 2012-05-17 MX MX2019011386A patent/MX382507B/es unknown
- 2012-05-17 RS RSP20191180 patent/RS59382B1/sr unknown
- 2012-05-17 AP AP2013007258A patent/AP3694A/xx active
- 2012-05-17 CA CA2836268A patent/CA2836268C/en active Active
- 2012-05-17 GE GEAP201213326A patent/GEP201706614B/en unknown
- 2012-05-17 PE PE2013002510A patent/PE20141161A1/es not_active Application Discontinuation
- 2012-05-17 DK DK12785811.6T patent/DK2716684T3/da active
- 2012-05-17 PL PL12785811T patent/PL2716684T3/pl unknown
- 2012-05-17 EP EP19176981.9A patent/EP3569636A1/en active Pending
- 2012-05-17 BR BR112013029616-0A patent/BR112013029616B1/pt not_active IP Right Cessation
- 2012-05-17 KR KR1020177007939A patent/KR20170034950A/ko not_active Withdrawn
- 2012-05-17 KR KR1020137033587A patent/KR20140074259A/ko not_active Ceased
- 2012-05-17 SI SI201231662T patent/SI2716684T1/sl unknown
- 2012-05-17 RU RU2013155582/15A patent/RU2582975C2/ru active
- 2012-05-17 AU AU2012257347A patent/AU2012257347A1/en not_active Abandoned
-
2013
- 2013-11-13 ZA ZA2013/08542A patent/ZA201308542B/en unknown
- 2013-11-13 IL IL229423A patent/IL229423B/en active IP Right Grant
- 2013-11-15 DO DO2013000266A patent/DOP2013000266A/es unknown
- 2013-11-15 CO CO13269426A patent/CO6801779A2/es not_active Application Discontinuation
- 2013-11-15 SV SV2013004582A patent/SV2013004582A/es unknown
- 2013-11-15 NI NI201300124A patent/NI201300124A/es unknown
- 2013-11-15 CR CR20130600A patent/CR20130600A/es unknown
- 2013-11-18 CL CL2013003305A patent/CL2013003305A1/es unknown
- 2013-11-18 US US14/082,947 patent/US10172952B2/en active Active
- 2013-12-17 MA MA36578A patent/MA35189B1/fr unknown
-
2015
- 2015-08-12 AU AU2015213303A patent/AU2015213303A1/en not_active Abandoned
-
2016
- 2016-05-10 JP JP2016094386A patent/JP2016175931A/ja active Pending
-
2017
- 2017-09-01 AU AU2017221883A patent/AU2017221883B2/en not_active Ceased
-
2018
- 2018-12-19 US US16/225,987 patent/US10493164B2/en active Active
-
2019
- 2019-09-20 CY CY20191100990T patent/CY1122190T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX339205B (es) | Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
| ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CL2013003227A1 (es) | “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct | |
| MX2009006786A (es) | Composiciones y metodos para el tratamiento de infecciones y tumores. | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| AR090456A1 (es) | Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos | |
| CU24350B1 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| GT201200126A (es) | Derivados de la cromenona con actividad anti-tumoral | |
| HN2011001195A (es) | Compuestos que expanden las celulas madre hematopoieticas | |
| DOP2012000314A (es) | Compuestos, composiciones de tiocetato y metodos de uso | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| WO2015148415A3 (en) | Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease | |
| AR099569A1 (es) | Derivados de insulina y los usos médicos de estos | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| CL2016000008A1 (es) | Tratamiento de lesiones inflamatorias de rosacea con ivermectina. | |
| MX360554B (es) | Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2. | |
| DOP2016000253A (es) | Nuevos compuestos | |
| BR112017008993A2 (pt) | métodos e composições especificamente para o tratamento de transtorno de déficit de atenção | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos |